Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

81. Is 45 really the new 50 in colorectal cancer screening?

Is 45 really the new 50 in colorectal cancer screening? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca June 29, 2020 (...) Is 45 really the new 50 in colorectal cancer screening? Clinical Question: Should we lower the age that average risk patients commence colorectal cancer screening from 50 to 45? Bottom Line: In developed countries, the incidence of colorectal cancer in persons under 50 years old has increased by 20-30% in the last 20 years. However, the absolute risk increase is only 1-4 per 100,000 persons. Screening average risk patients under age 50 should not be encouraged at this time. Evidence: • Population

2020 Tools for Practice

82. Larotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) - Addendum to Commission A19-90

(0) Liver carcinoma 1 1.12 [1.12; 1.12] 1 (100) Prostate cancer 1 NA [6.44 b ; 6.44 b ] 0 (0) Cancer of unknown primary 1 11.96 [11.96; 11.96] 1 (100) Primary CNS tumour d 24 NA [1.9 b ; 21.4 b ] 1 (4) a. Data are based on the ePAS4 population: patients with NTRK gene fusion (except patients with primary CNS tumours) who meet the following criteria: administration of = 1 dose of larotrectinib, = 1 measurable lesion at baseline as evaluated by the investigator, IRC assessment available. b (...) cancer b 15 15 (100) Colorectal cancer 8 8 (100) Thyroid cancer Melanoma 89 c 87 (98) c Breast cancer Gastrointestinal stromal tumour Bone sarcoma Cholangiocarcinoma Pancreatic cancer Appendix cancer Congenital mesoblastic nephroma Liver carcinoma Prostate cancer Cancer of unknown primary Primary CNS tumour a. Information is based on the safety population with NTRK gene fusion (Overall NTRK Fusion Cancers Safety Set). This comprises all patients with NTRK gene fusion who had received = 1 dose

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

83. Niraparib (ovarian cancer) - Addendum to Commission A19-88

Niraparib (ovarian cancer) - Addendum to Commission A19-88 www.iqwig.de - 404 - Seite nicht gefunden accessibility.navigation.meta IQWiG accessibility.navigation.main Brotkrumenpfad 404 - Seite nicht gefunden Seite nicht gefunden Die von Ihnen aufgerufene Seite existiert leider nicht. Bitte verwenden Sie die Navigation oder unsere , um den gewünschten Inhalt zu finden. Falls Sie Fragen haben, können Sie sich auch direkt über unser an uns wenden. Suche Suche Weitere Informationen Der IQWiG

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

84. Prostate cancer screening with the PSA test

screening 24 April 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - 1 Background Prostate cancer is a malignant change in the prostate; as it progresses, it can infiltrate directly adjacent tissue (seminal vesicle, urinary bladder, large intestine) and can form distant metastases. As measured by the number of new cases, prostate cancer is the most common tumour disease in men in Germany, making up 23.0% of all cancer cases. For 2016, the Robert Koch Institute estimated that about (...) 58 780 men received an initial diagnosis of prostate cancer [1]. Age is considered the most important risk factor for the development of prostate cancer [1, 2]. At a median age of onset of 72 years, prostate cancer occurs predominantly in advanced age; it is rarely found before the 45 th to 50 th year of life [1]. Every year, about 14 000 men in Germany die of the consequences of prostate cancer [1]. The prognosis of the disease decisively depends on the tumour stage as well as tumour typing

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

85. Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V

: appropriate comparator therapy; G-BA: Federal Joint Committee; SPC: Summary of Product Characteristics According to the S3 guideline “Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours”, cancers of the ovaries, fallopian tubes, and peritoneum are jointly classified in case of the same pathogenesis and histomorphology [3]. In the present dossier assessment, the term “ovarian cancer” therefore includes ovarian, fallopian tube and peritoneal cancer. From the options presented, the company chose (...) assessment. IQWiG employees involved in the dossier assessment ? Bent Müller ? Christiane Balg ? Tatjana Herrmanns ? Corinna Kiefer ? Katrin Nink ? Sabine Ostlender ? Volker Vervölgyi ? Carolin Weigel Keywords: Niraparib, Ovarian Neoplasms, Benefit Assessment, NCT01847274, NCT00753545, NCT01874353 Extract of dossier assessment A19-88 Version 1.0 Niraparib (ovarian cancer) 13 January 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

86. Increased risk of skin cancer with hydrochlorothiazide: what are the practical consequences?

Increased risk of skin cancer with hydrochlorothiazide: what are the practical consequences? Prescrire IN ENGLISH - Spotlight ''Increased risk of skin cancer with hydrochlorothiazide: what are the practical consequences?'', 1 July 2020 {1} {1} {1} | | > > > Increased risk of skin cancer with hydrochlorothiazide: what are the practical consequences? Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight Increased risk of skin cancer with hydrochlorothiazide: what are the practical consequences? Queries and Comments In 2018, Prescrire reported the findings of two case-control studies that showed an increased risk of non-melanoma skin cancers in patients treated with hydrochlorothiazide, a first-choice antihypertensive drug. Does the evidence available in 2020 affect this drug's harm-benefit balance in hypertension? In practice : Inform and monitor

2020 Prescrire

87. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions . 2020 Jul 20;38(21):2369-2379. doi: 10.1200/JCO.20.00793. Epub 2020 May 29. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

2020 EvidenceUpdates

88. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials

Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions . 2020 May 12;JCO1903217. doi: 10.1200/JCO.19.03217. Online ahead of print. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials

2020 EvidenceUpdates

89. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update | Journal of Clinical Oncology Search in: Menu > > > > Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.01399 Journal of Clinical Oncology - published online before print July (...) 14, 2020 PMID: Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update , MD 1 x Charles L. Loprinzi ; , MHSc 2 x Christina Lacchetti ; , MD 3 x Jonathan Bleeker ; , MD, PhD 4 x Guido Cavaletti ; , MSW 5 x Cynthia Chauhan ; , PharmD, PhD 6 x Daniel L. Hertz ; , PhD 7 x Mark R. Kelley ; , BS Pharm, RPh 8 x Antoinette Lavino ; , MD 9 x Maryam B. Lustberg ; , PhD, RN 10 x Judith A. Paice ; , MD 11 x Bryan P. Schneider ; , RN, PhD 6

2020 American Society of Clinical Oncology Guidelines

90. Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline

with implementation of these recommendations. Additional information is available at . INTRODUCTION Section: Esophageal cancer is the sixth most common cancer worldwide, with an estimated 450,000 deaths per year. There are 2 distinct histologic types of esophageal carcinoma: squamous cell carcinoma and adenocarcinoma. Esophageal squamous cell carcinoma is more common in East Asian and Middle Eastern countries, such as China, Iran, and Turkmenistan, whereas adenocarcinoma is more prevalent in Western countries (...) esophageal cancer have tumors that invade local structures or involve regional lymph nodes but no distant metastases (ie, American Joint Committee on Cancer [AJCC] stage ≥ T2 or N+, M0). Surgery has been the main curative treatment of resectable locally advanced esophageal cancer, but the overall prognosis is poor with esophagectomy alone, particularly in squamous cell carcinoma. For this reason, many studies have explored adjuvant and neoadjuvant therapy options ; these include radiation therapy (RT

2020 American Society of Clinical Oncology Guidelines

91. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

, UK. 14 Gustave Roussy, Université Paris Saclay, INSERM, Villejuif, France. PMID: 32353342 DOI: Item in Clipboard Full-text links Cite Abstract Background: Patients with HER2-positive breast cancer who have received two or more previous therapies for advanced disease have few effective treatment options. The monarcHER trial aimed to compare the efficacy of abemaciclib plus trastuzumab with or without fulvestrant with standard-of-care chemotherapy of physician's choice plus trastuzumab in women (...) with advanced breast cancer. Methods: This phase 2, three-group, open-label trial was done across 75 hospitals, clinics, and medical centres in 14 countries. Eligible patients were women aged 18 years or older, who had hormone receptor-positive, HER2-positive advanced breast cancer with unresectable, locally advanced, recurrent or metastatic disease, Eastern Cooperative Oncology Group performance status of 0 or 1, and who had previously received at least two HER2-targeted therapies for advanced disease

2020 EvidenceUpdates

92. Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients Full Text available with Trip Pro

Hematology and Oncology, Hospital for Children and Adolescents, University Hospital, Johann Wolfgang Goethe University, Frankfurt am Main, Germany. 2 Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA. 3 Department of Hematology and Oncology, Leeds Teaching Hospital, National Health Service Trust, Leeds, United Kingdom. 4 Centre for Reviews and Dissemination, University of York, Leeds, United Kingdom. 5 Columbia University/Herbert Irving Cancer Center, Pediatric (...) Oncology, New York, NY. 6 Pediatric Oncology Institute, GRAACC/Federal University of Sao Paulo, Sao Paulo, Brazil. 7 Infectious Diseases Unit, Department of Pediatrics, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Giannina Gaslini, Genova, Italy. 8 Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. 9 Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada. 10 Department of Pharmacy

2020 EvidenceUpdates

93. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Thromb Haemost Actions . 2020 Jul;120(7):1128-1136. doi: 10.1055/s-0040-1712098. Epub 2020 May 4. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis , , , , , , , , , , , Affiliations Expand Affiliations 1 Internal Vascular and Emergency Medicine - Stroke Unit, University

2020 EvidenceUpdates

94. Short-term Outcomes of Single-port Versus Multiport Laparoscopic Surgery for Colon Cancer: The SIMPLE Multicenter Randomized Clinical Trial

Short-term Outcomes of Single-port Versus Multiport Laparoscopic Surgery for Colon Cancer: The SIMPLE Multicenter Randomized Clinical Trial Short-term Outcomes of Single-port Versus Multiport Laparoscopic Surgery for Colon Cancer: The SIMPLE Multicenter Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Ann Surg Actions . 2020 Mar 20. doi: 10.1097/SLA.0000000000003882. Online ahead of print. Short-term Outcomes of Single-port Versus Multiport Laparoscopic Surgery for Colon Cancer: The SIMPLE Multicenter Randomized Clinical Trial , , , , , , , , Affiliations Expand Affiliations 1 Department of Surgery, Seoul St. Mary Hospital, College of Medicine, The Catholic

2020 EvidenceUpdates

95. An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting

. Patient summary: En bloc resection of bladder tumour (ERBT) is a surgical technique aiming to resect a bladder tumour in one piece. We included an international panel of experts to agree on the best practice of ERBT, and this will provide guidance to clinicians and researchers in the future. Keywords: Bladder cancer; En bloc resection of bladder tumour; Transurethral resection of bladder tumour; Urothelial carcinoma. Copyright © 2020. Published by Elsevier B.V. Similar articles Yang H, Lin J, Gao P (...) An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search

2020 EvidenceUpdates

96. The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis

, Montreal, Quebec, Canada. PMID: 32369854 DOI: Item in Clipboard Full-text links Cite Abstract Background: Low molecular weight heparins (LMWH) are often used as a first-line therapy for the prevention of thrombosis in cancer patients. Preclinical evidence from animal models suggests that LMWH may have antimetastatic properties. Clinical evidence of this effect is inconclusive. The objective of this systematic review is to evaluate the effect of LMWH on overall survival in patients with solid tumor (...) malignancies. Methods: MEDLINE, Embase, and The Cochrane Central Register of Controlled trials were searched from inception to November 26, 2018. We included randomized controlled trials that compared LMWH to placebo, a no-treatment arm, or a short-term prophylactic course of LMWH in adult patients with solid tumors. The primary outcome was overall survival. Secondary outcomes included progression-free survival, the occurrence of venous thromboembolism, and major bleeding events. The risk of bias

2020 EvidenceUpdates

97. Olaparib (breast cancer) - Addendum to Commission A19-57

Olaparib (breast cancer) - Addendum to Commission A19-57 1 Translation of addendum A19-97 Olaparib (Mammakarzinom) – Addendum zum Auftrag A19-97 (Version 1.0; Status: 12 December 2019). Please note: This translation is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 12 December 2019 1.0 Commission: A19-97 Version: Status: IQWiG Reports – Commission No. A19-97 Olaparib (breast cancer (...) ) – Addendum to Commission A19-57 1 Addendum A19-97 Version 1.0 Olaparib – Addendum to Commission A19-57 12 December 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Olaparib (breast cancer) – Addendum to Commission A19-57 Commissioning agency Federal Joint Committee Commission awarded on 26 November 2019 Internal Commission No. A19-97 Address of publisher Institut für Qualität und

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

98. Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V

with the appropriate comparator therapy (ACT) for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in adult patients whose tumours have Programmed Cell Death-Ligand 1 (PD-L1) expression = 1% and who have not received prior chemotherapy for the treatment of their metastatic disease. The research question for the benefit assessment presented in Table 2 resulted from the ACT specified by the G-BA. Table 2: Research question of the benefit assessment of atezolizumab (...) Neoplasms, Benefit Assessment, NCT02425891 Extract of dossier assessment A19-81 Version 1.0 Atezolizumab (breast cancer) 20 December 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of abbreviations v 2 Benefit assessment 1 2.1 Executive summary of the benefit assessment 1 2.2 Research question 4 2.3 Information retrieval and study pool 3 2.4 Results on added benefit 4 2.5 Probability and extent of added benefit 4 2.6 List of included

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

99. Ramucirumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V

to be in Barcelona Clinic Liver Cancer (BCLC) stage C. Patients in BCLC stage B could also be eligible if their disease was not amenable or refractory to locoregional therapy. Patients Extract of dossier assessment A19-73 Version 1.0 Ramucirumab (hepatocellular carcinoma) 28 November 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - 2 - with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 and with only mild liver impairment (Child Pugh class A) were enrolled (...) in BCLC stage C at randomization; patients in BCLC stage B could be eligible if their disease was not amenable or refractory to locoregional therapy. c: Patients with fibrolamellar carcinoma were excluded from the study. d: In the absence of a histologically confirmed diagnosis, patients had to have clinical, biochemical or radiological findings consistent with the diagnosis of liver cirrhosis on study entry, and a liver mass measuring at least 2 cm with characteristic vascularization seen on either

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

100. Predictive ability of modified Ottawa score for recurrence in patients with cancer-associated venous thromboembolism: From the COMMAND VTE Registry

Predictive ability of modified Ottawa score for recurrence in patients with cancer-associated venous thromboembolism: From the COMMAND VTE Registry Predictive ability of modified Ottawa score for recurrence in patients with cancer-associated venous thromboembolism: From the COMMAND VTE Registry - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Thromb Res Actions . 2020 Jul;191:66-75. doi: 10.1016/j.thromres.2020.04.047. Epub 2020 May 4. Predictive ability of modified Ottawa score for recurrence in patients with cancer-associated venous thromboembolism: From the COMMAND VTE Registry , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department

2020 EvidenceUpdates